Inflammatory Bowel Disease Drugs

Citation for published version:
Hooper, KM, Barlow, PG, Stevens, C & Henderson, P 2016, 'Inflammatory Bowel Disease Drugs: A Focus on Autophagy' Journal of Crohn's and Colitis. DOI: 10.1093/ecco-jcc/jjw127

Digital Object Identifier (DOI):
10.1093/ecco-jcc/jjw127

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published in:
Journal of Crohn's and Colitis

Publisher Rights Statement:
© European Crohn's and Colitis Organisation (ECCO) 2016. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Review Article

Inflammatory Bowel Disease Drugs: A Focus on Autophagy

Kirsty M. Hooper,* Peter G. Barlow,* Craig Stevens,** Paul Henderson,*b,c*

*aSchool of Life, Sport & Social Sciences, Edinburgh Napier University, Edinburgh, UK  *bChild Life and Health, University of Edinburgh, Edinburgh, UK  *cDepartment of Paediatric Gastroenterology and Nutrition, Royal Hospital for Sick Children, Edinburgh, UK

*Joint senior authors

Corresponding author: Dr Craig Stevens, BSc, PhD, FHEA, School of Life, Sport & Social Sciences, Edinburgh Napier University, Sighthill Campus, Sighthill Court, Edinburgh, EH11 4BN, UK. Tel.: 00 44 131 455 2930; email: C.Stevens@napier.ac.uk

Abstract

Inflammatory bowel disease [IBD] is characterized by chronic inflammation of the gastrointestinal tract. Medications such as corticosteroids, thiopurines, immunomodulators and biologic agents are used to induce and maintain remission; however, response to these drugs is variable and can diminish over time. Defective autophagy has been strongly linked to IBD pathogenesis, with evidence showing that enhancing autophagy may be therapeutically beneficial by regulating inflammation and clearing intestinal pathogens. It is plausible that the therapeutic effects of some IBD drugs are mediated in part through modulation of the autophagy pathway, with studies investigating a wide range of diseases and cell types demonstrating autophagy pathway regulation by these agents. This review will highlight the current evidence, both in vitro and in vivo, for the modulation of autophagy by drugs routinely used in IBD. A clearer understanding of their mechanisms of action will be invaluable to utilize these drugs in a more targeted and personalized manner in this diverse and often complex group of patients.

Keywords: Autophagy; drugs; IBD; Crohn’s disease

1. Introduction

The major inflammatory bowel diseases [IBD], Crohn’s disease [CD] and ulcerative colitis [UC], are characterized by chronic inflammation of the gastrointestinal [GI] tract and affect up to 1 in 250 people in the UK. A recent National Health Service [NHS] review estimated IBD treatment costs of £720 million per year, with roughly a quarter of these costs directly attributed to drug treatments. At present there is no cure for IBD, and medications are aimed at inducing and maintaining remission of disease by modifying inflammatory processes. The efficacy of current drugs for the treatment of IBD continues to come under scrutiny, as response to treatment often diminishes over time, resulting in disease complications. A recent review of European cohorts estimates that 10–35% of CD patients required surgery within 1 year of diagnosis and up to 61% by 10 years. Development of new drugs is a long and expensive process associated with high failure rates; therefore, making better use of drugs that have already been approved for clinical use is essential. The Crohn’s and Colitis Foundation of America has recently highlighted this need for research into optimizing medical therapies, with patient stratification and personalized medicine of key importance in this context. In order to improve the efficacy of existing drugs, a more comprehensive characterization of their mechanism of action is required. Here we give an overview of IBD drugs that have been linked to the modulation of autophagy, a cellular process that has been implicated in CD pathogenesis, and summarize what is currently known regarding their mechanism of action.

2. Aetiology of IBD

The aetipathogenesis of IBD remains poorly understood but is almost certainly multifactorial in nature, with genetic predisposition,
environmental triggers [such as smoking, antibiotics and diet] and a
dysregulated immune response to intestinal microflora all contribut-
ing.7 Genome-wide association studies [GWAS] have now identified
multiple susceptibility loci for CD and confirmed the previously rec-
ognized association of nucleotide-binding oligomerization domain-
containing protein 2 [NOD2], genes involved in T cell-dependent
immunity and autophagy, including autophagy-related protein 16-1
[ATG16L1], immunity-related GTPase family M protein [IRGM]
and leucine rich repeat kinase 2 [LRRK2].8 Genetic association with
the transcription factor x-box-binding protein 1 [XBP1], a key com-
ponent of the endoplasmic reticulum [ER]-stress response, with both
forms of IBD have also been identified and replicated.9 These genetic
studies have led to an increase in research linking autophagy dys-
regulation to CD pathogenesis.

2.1. Autophagy
Autophagy is an intracellular process that degrades excessive, dam-
gaged or aged proteins and organelles to maintain cellular homeosta-
sis.10 These homeostatic functions impact on many essential cellular
processes including development and differentiation, survival, senesc-
ence and innate and adaptive immunity, with dysregulated
autophagy linked to a multitude of diseases.11 When macroautophagy
[hereafter referred to as autophagy] is initiated, the isolation mem-
brane, an expanding lipid bilayer, forms a double membrane vesicle
[the autophagosome] around the cargo to be degraded [Figure 1].
The mature autophagosome then fuses with a lysosome to form an
autophagolysosome, in which lysosomal enzymes degrade the inner
membrane and cargo. The process of autophagy is controlled by
the coordinated activity of ATG [autophagy-related] proteins. The further detailed and complex molecular machinery involved in bio-
genesis of the isolation membrane and autophagosome is beyond
the scope of this focused review and has been discussed comprehen-
sively elsewhere12; however, it is appropriate to highlight the role of
ATG16L1 in this process. Two ubiquitin-like molecules, LC3 [micro-
tubule-associated proteins 1A/1B light chain 3A]/ATG8 and ATG12
are involved in autophagosome biogenesis. LC3/ATG8 is conjugated
to phosphatidylethanolamine [PE] to form lipidated LC3-II and is
associated with autophagosome formation. ATG12 is conjugated to
ATG5 and forms a complex with ATG16L1 [ATG16L1 complex].

The ATG16L1 complex is proposed to specify the site of LC3 lipida-
tion for autophagosome formation [Figure 1]11.

2.2. Autophagy signalling pathways
Autophagy is active at a basal level in most cell types to maintain
homeostasis, and this activity is modulated in response to a myriad
of stresses and stimuli that include starvation, hypoxia, infection
and ER stress.13 Autophagy is largely regulated, but not exclusively,
by the mTORC1 [mechanistic target of rapamycin complex 1] and
Beclin1/B cell lymphoma 2 [Bcl-2] signalling pathways [Figure 2].
The mTORC1 pathway plays a central role in the inhibition of
autophagy, for example blocking mTORC1 activity with the small
macrolide antibiotic rapamycin stimulates induction of autophagy.
Class I phosphatidylinositol 3-kinases [PI3K],Akt and Rax/Mek/Erk
signalling pathways are involved in the activation of mTORC1 and
subsequent inhibition of autophagy.14 mTORC1 inhibits autophagy
via phosphorylation of Unc-51 like autophagy activating kinase 1
[ULK1] and ATG13 to inhibit the ULK1-A TG13-FIP200 complex,
which is important for initiation of autophagosome formation.15
Conversely, AMP-activated protein kinase [AMPK] is involved in
the inhibition of mTORC1 and stimulates autophagy via phospho-
ylation of ULK1 at sites distinct from mTORC1.16 Activated ULK1
and AMPK subsequently phosphorylate Beclin1 for the induction
of autophagy.16,17 Beclin1 induces autophagy through the formation
of the class III PI3K complex consisting of Vps34-Yps15-Beclin1.18
Interaction of the class III PI3K complex with ATG14 is important
for recruitment of autophagy proteins, including the ATG16L1 com-
plex and LC3/ATG8, to the autophagosome membrane during early
stages of the pathway [Figure 2].12

Beclin1 was originally identified as an interacting protein with
Bcl-219, an anti-apoptotic protein that inhibits autophagy when it is in complex with Beclin1.20,21 In response to nutrient depriva-
tion, c-Jun N-terminal kinase [JNK]-1-mediated phosphoryla-
tion prevent Bcl-2 from binding to and inhibiting pro-
apoptotic proteins including Bcl-2 associated X protein [BAX] and
Bcl-2-antagonist/killer [Bak].22,23 Therefore, Bcl-2 phosphorylation

Figure 1. The autophagy pathway. During the initial stages of autophagy, the isolation membrane forms a double membrane vesicle [the autophagosome] around the cargo to be degraded. The mature autophagosome then fuses with a lysosome to form an autophagolysosome, in which cargo are degraded by lysosomal enzymes and subunits are recycled. Autophagy is controlled by the coordinated activity of ATG proteins. Two ubiquitin-like molecules, LC3 and ATG12, are involved in autophagosome biogenesis. LC3 is conjugated to PE to form lipidated LC3-II and is associated with the autophagosome outer membrane. ATG12 is conjugated to ATG5 and forms a complex with ATG16L1 [ATG16L1 complex]. The ATG16L1 complex is proposed to specify the site of LC3 lipidation for autophagosome formation.
can act as a switch between autophagy, a pro-survival response to cellular stress and apoptosis, a mechanism to limit damage to neighbouring cells under conditions of prolonged stress. A rheostat model proposed by Pattingre et al. suggests that when autophagy exceeds physiological levels, then autophagic-cell death can occur due to over-digestion of essential cellular components. The complex relationship between autophagy and apoptotic cell death has been reviewed elsewhere.

3. Autophagy and Crohn’s Disease

Xenophagy [a specific type of autophagy that degrades microorganisms] is central to the innate immune response. It can target and degrade intracellular pathogens, stimulate the production of host defence peptides and present antigens to initiate the adaptive immune response. During infection, microbe-associated molecular patterns [MAMPs] are detected by a family of proteins called pattern recognition receptors [PRRs] located within host cells. PRRs involved in xenophagy include the Nod-like receptors [NLRs], Toll-like receptors [TLRs] and sequestosome 1/p62-like receptors [SLRs].

The PRR NOD2 was the first gene to be linked to CD susceptibility in 2001, with the three most common CD-associated NOD2 single nucleotide polymorphism [SNP] variants [R702W, G908R and L1007f/s] identified in roughly one-third of patients. Furthermore, homoyzogous mutation of the NOD2 gene increases the risk of developing CD 20- to 40-fold. A SNP identified in NOD2, that encodes for a single amino acid substitution [R702W], has been modelled in hypomorphic mice. These mice do not spontaneously develop intestinal inflammation but do show evidence of Paneth cell dysfunction that is similar to Paneth cells from patients homozygous for the T300A allele. A recent functional study using a T300A knock-in mouse model has demonstrated that the T300A variant creates a caspase cleavage site, making NOD2 more susceptible to caspase-3-mediated degradation.

The majority of functional studies have focused on NOD2 and ATG16L1, which are among the strongest risk factors in CD. These studies have reported decreased autophagy levels in a range of cell types derived from CD patients, and cells harbouring NOD2 L1007f/s or ATG16L1 T300A variants exhibit a number of disrupted functions linked to autophagy, including impaired autophagosome formation and degradation of cytoplasmic microorganisms, defective presentation of bacterial antigens to CD4+ T cells and alterations in Paneth cell granule formation.

Importantly, in intestinal epithelial cells and dendritic cells [DCs] that harbour the NOD2 L1007f/s or ATG16L1 T300A variants, MDP-induced autophagy is diminished, leading to ineffective killing of pathogens such as Salmonella typhimurium, Shigella flexneri and Adherent Invasive Escherichia coli [AIEC]. It has been suggested this may be due to the inability of NOD2 L1007f/s to recruit ATG16L1 T300A protein and the autophagy machinery to kappa-light-chain-enhancer of activated B cells [NFκB] signalling and host defence peptide secretion. In 2007 the first autophagy gene, ATG16L1, was linked to CD susceptibility, followed by the identification of variants in autophagy genes including IRGM and LRRK2. An SNP identified in ATG16L1, that encodes for a single amino acid substitution [T300A], has been modelled in hypomorphic mice. These mice do not spontaneously develop intestinal inflammation but do show evidence of Paneth cell dysfunction that is similar to Paneth cells from patients homozygous for the T300A allele. A recent functional study using a T300A knock-in mouse model has demonstrated that the T300A variant creates a caspase cleavage site, making ATG16L1 more susceptible to caspase-3-mediated degradation.

The central pathways in autophagy regulation are mTORC1 and Beclin1/Bcl-2. Class I PI3K, via Akt and Ras/Mek/Erk signalling pathways phosphorylate Tuberin [TSC2] to promote Rheb-dependent activation of mTORC1. When active, mTORC1 inhibits formation of the ULK1-ATG13-FIP200 complex, which is necessary for initiation of autophagy. Conversely, AMPK is involved in the inhibition of mTORC1 and stimulates autophagy via phosphorylation of ULK1 at sites distinct from mTORC1. Bcl-2 is dissociated from Beclin1 due to JNK-1-dependent phosphorylation of Bcl-2. Bcl-2 is then free to inhibit apoptosis through binding of BAX and Bak. Beclin1 is free to bind Vps34-Vps15 [the mammalian homologue of Vps15 is p150] to induce autophagy. The Vps34-Vps15-Beclin1 complex binds to ATG14L to induce further ATG protein recruitment and elongation of the isolation membrane in the initial stages of autophagy. Activated ULK1 and AMPK can also directly phosphorylate Beclin1 for the induction of autophagy [not shown].

Figure 2. Autophagy regulation. The central pathways in autophagy regulation are mTORC1 and Beclin1/Bcl-2. Class I PI3K, via Akt and Ras/Mek/Erk signalling pathways phosphorylate Tuberin [TSC2] to promote Rheb-dependent activation of mTORC1. When active, mTORC1 inhibits formation of the ULK1-ATG13-FIP200 complex, which is necessary for initiation of autophagy. Conversely, AMPK is involved in the inhibition of mTORC1 and stimulates autophagy via phosphorylation of ULK1 at sites distinct from mTORC1. Bcl-2 is dissociated from Beclin1 due to JNK-1-dependent phosphorylation of Bcl-2. Bcl-2 is then free to inhibit apoptosis through binding of BAX and Bak. Beclin1 is free to bind Vps34-Vps15 [the mammalian homologue of Vps15 is p150] to induce autophagy. The Vps34-Vps15-Beclin1 complex binds to ATG14L to induce further ATG protein recruitment and elongation of the isolation membrane in the initial stages of autophagy. Activated ULK1 and AMPK can also directly phosphorylate Beclin1 for the induction of autophagy [not shown].
sites of bacterial entry at the cytoplasmic membrane. The increased levels of pro-inflammatory cytokines observed in CD patients have also been linked to autophagy dysregulation. Loss of functional ATG16L1 protein results in increased pro-inflammatory IL-1β and IL-18 production in murine studies and in human peripheral blood mononuclear cells. It has been suggested that when bound to NOD2, ATG16L1 acts as a modulator of NOD2 activity, shifting the balance between autophagy and cytokine production; loss of functional ATG16L1 shifts NOD2 activity towards pro-inflammatory signalling 40. Autophagy is required for presentation of antigens derived from degraded bacterial components to the adaptive immune system. This is of particular importance as dysregulation of T-cell responses are a key feature of CD pathogenesis. DCs from CD patients expressing the NOD2 L1007fs or ATG16L1 T300A variants have disrupted antigen sampling and processing and are incapable of antigen presentation via major histocompatibility complex [MHC] II.

Little is known about the function of IRGM and LRRK2 in CD. A deletion polymorphism immediately upstream of IRGM found in strong linkage disequilibrium with the most strongly CD-associated SNP, causes IRGM to segregate into CD risk variant [deletion] and protective variant [no deletion]. Subsequently it has been shown that a family of microRNAs [miRNAs], miR-196, that is overexpressed in the inflammatory intestinal epithelia of individuals with CD, downregulates the IRGM protective variant but not the risk-associated variant. Functionally, the loss of IRGM protective variant expression compromises autophagy and control of the intracellular replication of CD-associated AIEC. Interestingly, a recent study has placed IRGM in a central role for the orchestration of core autophagy machinery in response to microbial infection. It was shown that IRGM regulates the formation of a complex containing NOD2 and ATG16L1 that is necessary for the induction of xenophagy. The interaction of IRGM with NOD2 also stimulates phosphorylation cascades involving AMPK, ULK1 and Beclin1 that regulate autophagy initiation complex. LRRK2 expression is enriched in human immune cells and is increased in colonic biopsy specimens from patients with CD. Functionally, LRRK2 can enhance NFκB-dependent transcription, whereas small interfering RNA [siRNA] knockdown of LRRK2 in RAW 264.7 macrophages interferes with reactive oxygen species production and bacterial killing.

Common upstream signalling pathways regulate autophagy; however, its activation can have different functional outcomes that operate in a cell-type specific manner. Consistent with this conditional knockout mouse models of autophagy genes ATG16II and ATG3 are selectively important for the biology of the Paneth cell, with notable abnormalities observed in the granule exocytosis pathway. IRGM-deficient mice also exhibit abnormalities in the colon and ileum. LRRK2 deficiency confers enhanced susceptibility to experimental colitis in mice; however, this was associated with enhanced nuclear localization of the transcription factor nuclear factor of activated T cells [NFAT1], important for regulating innate immune responses. Specifically, it was found that there was aberrant activation of bone marrow-derived macrophages from the LRRK2 deficient mice following exposure to various stimulators of innate immunity. Clearly, a comprehensive understanding of the cell-specific nature of autophagy and autophagy-related proteins is essential for understanding its role in IBD.

3.1. ER stress and autophagy

ER stress results from unfolded and misfolded protein accumulation in the ER, with cells that naturally secrete large amounts of protein, such as Paneth cells, being more susceptible to ER stress. The ability of highly secretory cells to respond to and resolve the ER stress depends on the unfolded protein response [UPR]. Genetic studies have identified several ER stress/UPR genes that are associated with IBD, most notably XBP1, and there is evidence that ER stress levels are increased in the intestines of patients with IBD. Autophagy activity is high in Paneth cells and can act to counterbalance ER stress; therefore ER stress is a significant risk when the UPR or autophagy is not functional. Consistent with this, targeted deletion of either XBP1 or ATG16L1 in intestinal epithelial cells is associated with severe spontaneous CD-like transmural ileitis if both genes are compromised. Importantly, in Paneth cells of patients harbouring an ATG16L1 T300A risk allele, the ER-stress markers 78 kDa glucose-regulated protein [GRP78] and phospho-eukaryotic initiation factor 2α [eIF2α] were highly expressed. This has led to suggestion that the ATG16L1 T300A variant may define a specific subtype of patients with CD, characterized by Paneth cell ER stress, which correlates with bacterial persistence and reduced antimicrobial functionality. Interestingly, a recent study has demonstrated a direct link between NOD1/2 and ER stress-induced inflammation. In mouse and human cells, the ER stress inducers thapsigargin and dithiothreitol trigger the production of the pro-inflammatory cytokine IL-6 in a NOD1/2-dependent manner. Furthermore, IL-6 production induced by the intracellular pathogen Brucella abortus, which also induces ER stress, was dependent upon NOD1/2-signalling. Therefore, it is significant that major risk factors for CD, ATG16L1 and NOD2, functionally intersect with ER stress and the UPR. The convergence between autophagy and ER stress provides new opportunity for the treatment of IBD. For example, modulation of the UPR in combination with autophagy inducers is a promising therapeutic strategy.

3.2. Current IBD drugs

The mechanism of action of current IBD drugs remains incompletely understood [Table 1]. However, progress has been made in recent years towards characterising their effects, with the modulation of immunoregulatory signalling pathways often linked directly or indirectly to the autophagy response [Table 2]. Importantly these heterogeneous studies have been conducted in a wide variety of disease settings and cell types; highlighting the need to explore the effect of these drugs on autophagy pathway activity in the context of IBD.

3.3. Corticosteroids

The first-line treatment for CD and UC is often corticosteroids. Corticosteroids downregulate pro-inflammatory cytokines including IL-1, IL-6 and tumor necrosis factor alpha [TNFα], by inhibiting the transcription of genes involved in their production and affecting the stability of messenger RNA [mRNA] to inhibit protein expression. Furthermore, inflammatory signalling induced by NFκB is decreased due to interaction with corticosteroid receptors. Although there is limited knowledge of the effect of corticosteroids on autophagy in IBD, there has been some progress in understanding their effect on autophagy in other disease settings.

The clinical response to corticosteroids in UC patients has been linked to mTORC1 [Figure 3]. In a transcriptomics study, it was observed that miRNA and mRNA profiles in the rectal mucosa of UC patients differed between responders and non-responders to corticosteroid treatment. The mRNA with the most significant differential expression between groups was DNA damage-induced transcript 4 [DDIT4], an inhibitor of mTORC1 activity, which was upregulated in responders after 3 days of corticosteroid treatment.
Corticosteroids
- Prednisolone, budesonide
- Downregulation of pro-inflammatory cytokines
- Interference with NFκB inflammatory signalling
- Dexamethasone induced autophagy in T lymphocytes
- Inhibition of autophagy in human monocytes infected with Aspergillus fumigatus
- Sulphasalazine decreased autophagy via NFκB inhibition in an in vivo murine model of cachectic cancer
- Sulphasalazine induced autophagic cell death through inhibition of the Akt pathway and activation of the ERK pathway in an oral squamous cell carcinoma cell line
- Autophagy is activated in hepatocytes treated with thiopurines
- Increased autophagy in epithelial cells of animal colitis model due to rapid local bacterial conversion of thioguanine pro-drug to active metabolite
- Cyclosporin cytotoxicity induced autophagy as a survival process in malignant glioma cells, primary cultured human renal tubular cells and in vivo with rat kidneys, and in kidney proximal tubule epithelial cells
- Cyclosporin induced autophagic-cell death in a rat pituitary cell line
- Tacrolimus induced autophagy in mouse neuroblastoma and microglial cell lines and in the brains of tacrolimus-treated mice
- Anti-TNF antibodies can induce reactivation of TB, at least partially due to decreased autophagy
- TNF stimulates autophagy in synovial fibroblasts from rheumatoid arthritis patients
- In skeletal muscle, in atherosclerotic vascular smooth cells, in trophoblastic cells and in mouse macrophages

Furthermore, three miRNAs that were differentially expressed in responders could potentially target DDIT4.

In the hippocampus of rats, it has also been shown that corticosterone treatment affects mTORC1 signalling pathways. In this study, corticosterone upregulated the expression of DDIT4, as well as FK506-binding protein 51 [FKBP51], but downregulated DDIT3. DDIT4 and FKBP51 inhibited mTORC1 activity, whereas the pro-apoptotic transcription factor DDIT3 is itself regulated by mTORC1. In agreement, Wang et al. found that dexamethasone treatment of in vivo skeletal muscle and cultured L6 myoblasts increased DDIT4 expression and confirmed that DDIT4 downregulates mTORC1 activity. Another study, investigating the effects of dexamethasone treatment on T lymphocytes from healthy donors, found that there was a reduction in mTORC1 expression. Taken together, these studies strongly suggest that the mTORC1 pathway and autophagy play an important role in the response to treatment with corticosteroids.

Corticosteroid treatment is often associated with secondary osteoporosis and several studies have investigated the effects of corticosteroids on osteocyte cell fate. It has been shown in vitro and in vivo that low doses of prednisolone and dexamethasone induce autophagy in osteocytes and this is associated with osteocyte viability. However, higher doses of corticosteroids induce apoptosis, suggesting that autophagy may act as a protective mechanism against the cytotoxic effects of corticosteroids.

Autophagy is also activated in spinal cord injuries along with apoptosis and necrosis; however, rats treated with methylprednisolone exhibited decreased autophagy post-SCL. The effects of methylprednisolone on autophagy in this study may therefore be attributed to direct inhibition of autophagy or to a decrease in inflammation associated with injury, which indirectly reduces autophagy.

Corticosteroids are also used to treat lymphoid malignancies by blocking cell proliferation and inducing apoptosis in immature T cells. It has been shown that glucocorticoids induce autophagy in...
immature T cell populations, lymphoid cell lines and primary leukaemia cells. The dexamethasone-induced increase in autophagy was also associated with inhibition of mTORC1, possibly through regulation of the Src kinase Fyn. Swerdlow et al. suggested that a contributing factor to dexamethasone-induced autophagy could be metabolic stress caused by reduced glycolysis and glucose uptake in corticosteroid-treated lymphocytes [Figure 3]. Autophagy stimulation by glucocorticoids is relevant for treatment of lymphoid malignancies as it is intimately linked to the induction of apoptosis in T lymphocytes. Corticosteroids are able to induce apoptosis in immature T lymphocytes, as these cells lack the inhibitor of apoptosis protein Bcl-2. When Bcl-2 was overexpressed in immature T lymphocytes, dexamethasone-induced apoptosis was shown to be inhibited. Although Bcl-2 usually inhibits autophagy by binding to Beclin1 [Figure 2], it has been shown that overexpression of Bcl-2 in immature T lymphocytes can increase autophagy levels, presumably due to inhibition of apoptosis. Furthermore, autophagy induction prolonged the survival of dexamethasone-treated cells, and autophagy inhibition decreased survival time. In contrast, Laane et al. found that autophagy played a positive role in dexamethasone-induced apoptosis in lymphoid leukaemia cells. In this study, dexamethasone induced cell death through promyelocytic leukaemia [PML] protein-dependent dephosphorylation of the autophagy inhibitor Akt, stimulating the induction of autophagy [Figure 3].

Investigating fungal pathogen elimination in human monocytes demonstrated that corticosteroids could block autophagy protein recruitment to pathogen-containing phagosomes. Detection of the fungal ligand β-glucan by Dectin-1 receptors triggered Syk kinase-dependent production of reactive oxygen species [ROS], which stimulate autophagy when cells are infected by Aspergillus fumigatus. When autophagy was directly inhibited, or cells were treated with corticosteroids [in vivo and ex vivo], phagosome maturation [including fusion with the lysosome] and A. fumigatus killing were impaired. This highlights the importance of autophagy as a defence mechanism against fungal infections, but contradicts studies suggesting that autophagy is induced by corticosteroid treatment. Whereas this study focused on the effects of corticosteroids on xenophagy with A. fumigatus, other studies investigating T lymphocytes focused on non-selective macroautophagy induced by cellular stress. The contrasting results could be due to differences between the types of immune cells investigated, the disease pathogenesis, the types of corticosteroids used or the different types of autophagy that were investigated, and serves to highlight the cell-type specific nature of autophagy and the need to investigate the effect of corticosteroids on cell types that are relevant to IBD.

3.4. Aminosalicylates

Aminosalicylates are effective as first-line drugs to induce and maintain remission in mild to moderate cases of UC. Despite a lack of evidence for their efficacy in CD treatment, they are often prescribed as adjuvant therapy due to minimal side effects, low cost and chemo-preventative properties. Sulphasalazine or salicylazosulphapyridine [SASP] was originally developed for rheumatoid arthritis and contains 5-aminosalicylate [5-ASA] bound to sulphapyridine. Sulphapyridine exhibits direct antimicrobial activity and treatments with sulphapyridine have been linked to alterations in faecal bacterial profiles. Sulphapyridine has been associated with additional adverse effects, leading to the development of other forms of aminosalicylates including mesalazine. These consist of only the active moiety of SASP and does not contain sulphapyridine; pro-drugs of mesalazine, for example balsalazide and olsalazine, are also in use. The anti-inflammatory activities of 5-ASA include the scavenging of damaging ROS, upregulation of endogenous antioxidant systems, inhibition of leukocyte motility, leukotriene and platelet activation, interference with NFκB, IL-1 and TGF-β, inhibition of nitric oxide formation, prevention of mitochondrial damage and colonic epithelial cell-cycle arrest in S-phase. In theory, many of these activities could directly or indirectly affect autophagy.

Figure 3. Current inflammatory bowel disease drugs modulation of autophagy pathways. Refer to the text and Table 2 for details.
due to a reduction of cellular stress. One study, investigating sulphasalazine as an NFκB inhibitor in an in vivo murine model of cancer cachexia, reported a decrease in autophagy.79 [Figure 3]. This could be due to a direct effect of NFκB inhibition, as NFκB signalling regulates autophagy in a context-dependent manner,79 or through one or more of the other pathways regulated by sulphasalazine. In addition, this response may be specific to the disease or to the muscle tissues being examined in murine models. In contrast, Han et al.72 reported that sulphasalazine treatment in an oral squamous cell carcinoma [OSCC] cell line, HSC-4, induced autophagic cell death through inhibition of the Akt pathway and activation of the ERK pathway [Figure 3]. The seemingly opposing effects of sulphasalazine observed in these studies may be due to differences in dosage. Dosage is extremely difficult to compare between in vitro and in vivo studies; however, it is possible that the induction of autophagic cell death observed by Han et al.72 may be representative of a concentration range that is cytotoxic.

3.5. Thiopurines

Thiopurines, including azathioprine, 6-mercaptopurine and 6-thioguanine, are immunosuppressant drugs used to treat IBD.73 They have a relatively slow onset but can maintain remission in moderate to severe cases of CD and have also shown some effectiveness for the induction of remission.74,75 The commonly used pro-drug azathioprine is converted to 6-mercaptopurine [6-MP] by glutathione in the intestinal wall. Through a multi-step enzymatic pathway, the drug is broken down to thiopurine metabolites, thioguanine nucleotides [TGN] and methylthiopurine nucleotides [MMPN]. These nucleotides act as purine antagonists causing the inhibition of DNA, RNA and protein synthesis, which results in immunosuppression and cytotoxicity.76 Azathioprine can also generate 6-thioguanine GTP, which has been shown to induce T cell apoptosis through co-stimulation of the CD28 receptor due to blockage of Ras-related C3 botulinum toxin substrate [Rac1] activation of NFκB.77 Erythrocyte concentrations of thiopurine metabolites are now carefully monitored in many centres, to maintain therapeutic levels and to assess adherence, as increases in blood concentration have been associated with hepatotoxicity.77 Other adverse severe effects associated with thiopurines are pancreatitis and myelosuppression,78 with 15–20% of patients treated with thiopurines having to discontinue treatment due to these side effects.79

Due to the severe adverse effects of thiopurines, a potential protective role for autophagy in hepatocytes has been investigated. Autophagy is activated in hepatocytes treated with thiopurines, possibly as a secondary response to the hepatotoxic effects of the drug [Figure 3]; however, it could also indicate that autophagy is directly modulated to balance immune responses in patients.78,79 Despite the lack of understanding of the mechanism of action of thiopurines, it has been shown that autophagy has a protective role in hepatocytes during thiopurine therapy,79 suggesting that a combination treatment of thiopurines with drugs that induce autophagy may reduce their adverse effects, enhancing their efficacy and safety. A very recent study has correlated ATG16L1 genotype and response to thiopurines in two IBD cohorts and found that the ATG16L1 risk variant associates with response to thiopurine treatment specifically in patients with CD but not with UC.79 Furthermore, a defect in the autophagosomal regulation of active Rac1, a member of the Rho family of GTPases linked to the regulation of diverse cellular functions including cytoskeletal rearrangement, underlies the association between ATG16L1 and CD through decreased myeloid cell migration.79 As thiopurine can inhibit Rac1 activity, the authors suggest that ATG16L1 genotyping may be used to identify patients who would benefit from thiopurine treatment. In another new study, the rapid local bacterial conversion of thioguanine pro-drug to active metabolite was shown to augment autophagy in epithelial cells, resulting in increased intracellular bacterial killing and decreased intestinal inflammation and immune activation in spontaneous and induced animal colitis models.80

3.6. Methotrexate, cyclosporin and tacrolimus

Methotrexate, cyclosporin and tacrolimus are immunomodulatory drugs used mainly as second-line treatments to maintain remission in severe, steroid-refractory CD, with more recent evidence suggesting a role for tacrolimus in UC.81 Methotrexate inhibits DNA and RNA synthesis in rapidly dividing cells, and cyclosporin and tacrolimus alter IL-2 transcription causing reduced T cell activity.82 Although some evidence suggests that cyclosporin and tacrolimus modulate autophagy as part of their mechanism of action, no link has been identified between methotrexate and autophagy modulation.

Cyclosporin, originally used to prevent organ transplant rejection, acts by blocking lymphocyte and other immune cell activation.83 As this drug has very cytotoxic effects, several studies have shown that treatment with cyclosporin can induce autophagy in response to the toxicity either as a survival process or as part of a cell death mechanism.84,85 Toxic levels of cyclosporin induced autophagy in vivo and in vitro in malignant glioma cells.86 This was accompanied by mTORC1 inhibition and an ER stress response, with blockage of ER signalling decreasing accumulation of the autophagy marker LC3-II [Figure 3]. Furthermore, when autophagy is inhibited by blocking ULK1, ATG5 or ATG7, cyclosporin-induced cell death was shown to increase.87 These results suggest that autophagy is induced as a protective response to the cytotoxic effects of cyclosporin.

In a study of cyclosporin-induced nephrotoxicity, ER stress-dependent autophagy induction [Figure 3] has been demonstrated in primary cultured human renal tubular cells and in vivo within rat kidneys.88 In addition, cyclosporin can cause chronic metabolic stress, which leads to autophagy induction in kidney proximal tubule epithelial cells.89 In this study, autophagy-competent cells allow for metabolic adaptation to cyclosporin treatment, whereas autophagy deficiency resulted in cyclosporin-induced deterioration of the tricarboxylic acid [TCA] cycle and the overall energy status of the cell. In a rat pituitary cell line model, cyclosporin induced apoptosis and autophagic-cell death in a dose-dependent manner.89 From these studies, it appears that autophagy is stimulated by cyclosporin only as a secondary response to the drug’s cytotoxic effects. The mechanism of action of tacrolimus, also known as FK506, is similar to that of cyclosporin as both drugs inhibit the protein phosphatase calcineurin to block T cell function and IL-2 transcription. FK506 inhibits calcineurin by forming a complex with the immunophilin FKBP12 [FK506 binding protein], which is involved in immunoregulation.87 FKBP12 is also the direct target of rapamycin, an inhibitor of mTORC1. A recent study by Ge et al.88 investigating a novel activator of mTORC1, 3-benzyl-5-[[2-nitrophenoxy]-methyl]dihydrofuran-2[3H]-one [3BDO], demonstrated that 3BDO could activate mTORC1 by occupying the rapamycin-binding site in FKBP12.89 This study suggested that FK506, through a mechanism involving the formation of an FK506-FKBP12 complex, has the potential to act as an mTORC1 activator and autophagy inhibitor [Figure 3]. In another study investigating the use of FK506 as a novel therapeutical for prion infections, FK506 was shown to induce autophagy in mouse neuroblastoma [N2a58] and mouse microglial [MG20] cell lines and in the brains of mice.90 FK506 treatment significantly increased LC3-II, ATG3, ATG7 and autolysosome formation,
concomitant with decreased prion protein levels in cell cultures and increased survival of mice due to delayed accumulation of prion proteins.96

3.7. Biologic agents
Overproduction of pro-inflammatory cytokines and chemokines are a common feature associated with inflammatory diseases. Monoclonal antibodies that target and neutralise cytokines such as TNFα, IL-12, IL-23, IL-21, IL-22, IL-32 and IFN-γ, with a view to decreasing pro-inflammatory signaling, are used for the treatment of IBD.97 These biologic agents are usually reserved for the treatment of refractory CD or steroid-dependent patients to induce and maintain remission.

The most commonly used biologic agent for IBD is the anti-TNFα antibody, infliximab. Other anti-TNFα treatments approved for treatment of IBD patients include adalimumab, golimumab for UC only, and certolizumab pegol, which is approved in the USA, Switzerland and Russia. Anti-TNFα biosimilars, which are cheaper versions of licensed biologic agents whose patents have now expired, have also recently been developed.98 TNFα plays a major role in modulating the inflammatory response, and while the effects of TNFα have been extensively studied in a variety of cell types, its mechanism of action in the gut remains unknown. One confirmed effect of TNFα is the modulation of autophagy, which has been observed in synovial fibroblasts from rheumatoid arthritis patients,99 in skeletal muscle,100 in atherosclerotic vascular smooth cells101 and in trophoblastic cells.102 The effect of TNFα on mitophagy, a specific type of autophagy that involves the degradation of mitochondrial proteins and the mitochondrial organelle, has also been demonstrated in mouse macrophages.103 This study found that macrophages activated by TNFα have increased mitophagy, resulting in increased mitochondrial protein degradation and presentation to T cells via MHC I on the cell surface of the macrophages. As macrophages play a crucial role in innate immunity and inflammation within the gastrointestinal tract, further investigation of the effects of TNFα on autophagy in this cell type will be particularly relevant to IBD.

Taken together, these studies suggest that anti-TNF agents would inhibit autophagy [Figure 3]. Although there are no studies that have directly confirmed this, there is support for this hypothesis; anti-TNF agents can induce reactivation of Mycobacterium tuberculosis, at least partially due to decreased autophagy.97 This effect is likely due to the protective antibacterial and anti-inflammatory roles of autophagy in epithelial cells infected with this non-motile bacillus.98 It is worth noting however, that TNFα can also have inhibitory effects on autophagy in some contexts. A study investigating the effects of elevated TNFα on congestive heart failure in H9C2 rat cardiomyoblasts found that, although TNFα induces autophagy, autophagic protein degradation is disrupted, as evidenced by accumulation of p62 and increased ubiquitin-proteasome pathway activity.104 Additionally, Andrographis paniculata plant extract [HMPL-400], which is currently being studied in IBD trials for reduction of TNFα, IL-1β, IFN-γ and IL-22 expression, has been shown to inhibit autophagy in cancer.105 This may be due to the reduction of cytokines or another mechanism affected by HMPL-400.

4. Conclusions
The modulation of autophagy represents an exciting therapeutic option for the treatment of IBD, and evidence is already emerging that drugs currently used for the treatment of IBD can affect the autophagy pathway. The cross-talk between autophagy and ER stress offers new options for how IBD could be targeted, and combination treatments aimed at modulating both the UPR and autophagy warrant further investigation. However, to date there is little evidence that modulation of autophagy can be directly linked to amelioration of disease, with only one published case study of the mTORC1 inhibitor sirolimus [rapamycin] improving symptoms and healing in a patient with severe refractory CD.106 A major caveat is that autophagy is cell type specific, which makes it difficult to mechanistically link drug-induced autophagy to modulation of disease. Irrespective of this there is a pressing need to determine how these drugs modulate the autophagy pathway, specifically in patients with known mutations in the genes regulating the autophagy apparatus, and this must begin with consolidating studies in an in vitro setting in cell types directly relevant to IBD. A more comprehensive understanding of their mechanisms of action will undoubtedly allow for better-informed decisions regarding suitability of drug treatment for IBD on a patient-to-patient basis.

Funding
KMH is supported by a Crohn’s in Childhood Research Association [CICRA] PhD studentship [PhD/S/2014/1]. PH is supported by an NHS Research Scotland Career Researcher Fellowship.

Conflict of Interest
None.

Author Contributions
KMH, PGB, CS and PH drafted the article and revised it critically for important intellectual content.

References


